Adam Marc Bernheim MD, Abstract Co-Author: Nothing to Disclose

Florian J. Fintelmann MD, FRCPC, Presenter: Nothing to Disclose

Subba Rao Digumarthy MD, Abstract Co-Author: Nothing to Disclose

Inga T. Lennes, Abstract Co-Author: Nothing to Disclose

Mannudeep K. S. Kalra MD, Abstract Co-Author: Nothing to Disclose

Jo-Anne O. Shepard MD, Abstract Co-Author: Consultant, Agfa-Gevaert Group

Minor but imporant differences exist among low dose CT lung cancer screening trials Eligibility criteria of USPSTF slightly differ from prominent medical societies Successful implementation of a screening program requires careful organization, from patient education to follow up, and requires a step-wise approach New technologies of dose reduction, nodule detection, and biomarkers make screening safer and more efficient

Salient differences between European and American clinical trials Eligibility criteria as per major medical societies Essentials (pillars) for a lung cancer screening program, organized in a easy to understand format, covering all aspects, from hospital administration support to educational initiatives, management guidelines, and reimbursement Summarize guidelines and lexicon for standardized reporting Potential integration of emerging dose reduction technology, nodule detection and biomarkers Do radiologists need dedicated training to read screening CTs Conclusion: The exhibit provides the rationale for Lung Cancer Screening, and requisites for starting a successful lung cancer screening program organized in tables, charts, figures and examples for an international audience with practical pointers for both novice and expert

http://abstract.rsna.org/uploads/2014/14003154/14003154_1bi4.pdf

Bernheim, A, Fintelmann, F, Digumarthy, S, Lennes, I, Kalra, M, Shepard, J, Rationale and Logistics of Lung Cancer Screening.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003154.html